Azitra, Inc. - 8-K Filing

Azitra reports Q3 2026 net loss of $3.0 million and announces positive ex vivo results for ATR-COSF cosmetic program. (Items: 2.02 and shall not be deemed “filed” for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended)

SEC EDGAR ·

Tickers: $AZTR

Read the full article at SEC EDGAR

More Regulatory news